SecBot SecBot
DEFA14A ·Filed Apr 30, 2026

SNDX

Syndax Pharmaceuticals Inc
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-197877
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for the actual definitive proxy statement (DEF14A) and any related SC 13D filings to understand the specific activist demands and board proposals. The cross-filing amplifier signals suggest elevated probability of a contested proxy fight, watch for dissident nominee slate and management response.

DirectionNeutral
Confidencelow
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.11
T+0 close · Apr 30, 2026 · via day close
Latest settled
+2.72%
T+60 · $19.63
Vs SPY
−0.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $19.11entry
  2. T+1 · 7mo ago +4.45%α +4.79% · $19.96
  3. T+5 · 6mo ago +7.48%α +5.14% · $20.54
  4. T+20 · 6mo ago −1.36%α −6.64% · $18.85
  5. T+60 · 4mo ago +2.72%α −0.35% · $19.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Syndax Pharmaceuticals filed a DEFA14A (additional definitive proxy soliciting materials) on April 30, 2026. The filing is a definitive additional proxy statement, but the actual document content is unavailable, only the SEC filing header and metadata are provided. The filing type suggests ongoing proxy solicitation activity, but without document text, no specific proposals, activist demands, or financial figures can be extracted.

Key Facts

  • Filed DEFA14A on April 30, 2026
  • Filed by Syndax Pharmaceuticals Inc (ticker: SNDX)
  • Document content was not available for analysis
  • Market cap: $1.8B with 95% analyst bullish consensus
  • Cross-filing context indicates dissident proxy activity (activist context, DEF14A context, executive change context, preliminary context), all flagged as amplifiers

Financial Impact

No financial figures available from filing documents

Risk Factors

  • Potential activist campaign could lead to board changes or strategic review
  • Uncertainty due to lack of document content

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-197877
Document: 0001193125-26-197877-index-headers.html0001193125-26-197877
Document: 0001193125-26-197877-index.html0001193125-26-197877
Document: 0001193125-26-197877.txt0001193125-26-197877

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026